STOCK TITAN

Nanox to Report Fourth Quarter 2022 Financial Results on March 9, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

NANO-X IMAGING LTD (NASDAQ: NNOX) plans to announce its Q4 financial results for the period ending December 31, 2022, on March 9, 2023, before the market opens. CEO Erez Meltzer and CFO Ran Daniel will conduct a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The earnings call can be accessed via registration and a live webcast link available on the company's Investor Relations website. Nanox focuses on making diagnostic imaging affordable and accessible worldwide, utilizing its proprietary Nanox.ARC and Nanox.CLOUD technologies.

Positive
  • Nanox is set to report Q4 2022 financial results, indicating ongoing business operations.
  • The company aims to improve access to diagnostic imaging, potentially widening its market reach.
Negative
  • No specific financial metrics are provided in the PR, which may raise investor concerns.

NEVE ILAN, Israel--(BUSINESS WIRE)-- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX) will report its financial results for the fourth quarter ended December 31, 2022 before market on Thursday, March 9, 2023. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.

Interested parties may register for the conference call using the following link: Nanox Q4 2022 Earnings Registration Link. You may access the live webcast of the conference call by using the following link: Nanox Q4 2022 Earnings. The link will also be posted in the Investor Relations section of the Nanox website at Events and Presentations.

About Nanox:

Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. The vision of Nanox is to increase the early detection of medical conditions that are discoverable by medical image technologies based on X-rays, which Nanox believes is key to increasing early prevention and treatment, improving health outcomes, and, ultimately, saving lives. Nanox is developing a holistic imaging solution, which includes the Nanox System, comprised of the Nanox.ARC using its novel MEMs X-ray source technology, and the Nanox.CLOUD, a companion cloud software, integrated with AI solutions and teleradiology services. For more information, please visit www.nanox.vision.

Forward-Looking Statements:

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the recent acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; and (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; and (x) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release.

Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this report to conform these statements to actual results or to changes in the Company’s expectations.

Investors:

Mike Cavanaugh

ICR Westwicke

IR@nanox.vision

Media:

Rachael Roselli

ICR Westwicke

NanoxPR@icrinc.com

Source: NANO-X IMAGING LTD

FAQ

When will NANO-X IMAGING LTD report its fourth quarter 2022 financial results?

NANO-X IMAGING LTD will report its Q4 2022 financial results on March 9, 2023.

What time is the NANO-X IMAGING LTD conference call to discuss Q4 2022 results?

The conference call will take place at 8:30 a.m. ET on March 9, 2023.

How can I access the NANO-X IMAGING LTD Q4 2022 earnings call?

The earnings call can be accessed through a registration link and a live webcast available on the company’s Investor Relations website.

What is the focus of NANO-X IMAGING LTD's business?

NANO-X IMAGING LTD focuses on making diagnostic imaging more accessible and affordable using its proprietary technologies.

NANO-X IMAGING LTD Ordinary Shares

NASDAQ:NNOX

NNOX Rankings

NNOX Latest News

NNOX Stock Data

389.76M
53.26M
9%
18.67%
12.39%
Medical Devices
Healthcare
Link
United States of America
Petah Tikva